Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 06:30:00 11/12/2025 GMT			5-day change	1st Jan Change
2,661.00 ^JPY	-0.63%		-1.24%	+19.92%

12-10	Fed Outlook, Catalyst Dearth Cap Asian Stock Markets	MT
12-10	Japan's Topix index touches record high in tentative trade before Fed, BOJ	RE

Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says

Published on 05/07/2025 at 06:25 am BST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shionogi & Co., Ltd.

12-10	Fed Outlook, Catalyst Dearth Cap Asian Stock Markets	MT
12-10	Japan's Topix index touches record high in tentative trade before Fed, BOJ	RE
12-01	Shionogi & Co Completes Acquisition of Japan Tobacco's Pharma Business	MT
12-01	Japan Tobacco Completes Pharmaceutical Business Transfer to Shionogi	MT
11-30	Shionogi & Co., Ltd. completed the acquisition of Pharmaceutical business of Japan Tobacco Inc from Japan Tobacco Inc..	CI
10-31	Shionogi & Co., Ltd. to Establish the Central Pharmaceutical Research Institute and the Development Business Division	CI
10-31	Shionogi & Co., Ltd. Announces Management Appointments	CI
10-27	Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2025, Payable on December 01, 2025	CI
10-27	Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
10-27	Shionogi & Co.'s Attributable Profit Edges Up Fiscal H1	MT
10-27	Shionogi to Absorb Manufacturing Subsidiary in 2027 to Strengthen Supply Chain	MT
10-20	Shionogi & Co., Ltd. Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-To-Treat Infections	CI
09-26	Japan's Topix posts record-high close despite US tariffs on pharma	RE
09-26	US, European pharma stocks steady after Trump's tariff move, Asia slips	RE
09-26	Japan's Topix hits record high despite US tariffs on pharma	RE
09-17	Shionogi strengthens position by acquiring Torii
09-03	Nikkei Ends Lower as Ishiba Ally Quits, Nvidia-Led Tech Drop Hurts Mood	MT
09-03	FDA Accepts Shionogi's Application for First Oral COVID-19 Prevention Drug	MT
09-03	Fda accepts Shionogi's ensitrelvir nda for review as first oral therapy for prevention of Covid-19 following exposure	RE
09-02	FDA Accepts Shionogi's Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Application	CI
08-31	Shionogi & Co., Ltd. acquired 54.84% stake in Torii Pharmaceutical Co., Ltd. from Japan Tobacco Inc..	CI
08-08	Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs, Nikkei reports	RE
07-28	Shionogi & Co's Profit Rises 29% in Fiscal Q1	MT
07-24	Shionogi-Backed ViiV Says 89% in HIV Trial Prefer Long-Acting Cabenuva	MT
07-22	StemRIM Completes Patient Enrollment for Phase 2 Trial of Orphan Drug Redasemtide in Epidermolysis Bullosa	MT

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

02-01 - Q3 2025 Earnings Release (Projected)

More about the company